Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944147 | 0.85 | TAS1R3 (0.58) | PTGFRNPC1MEN1KMT2ATAS1R3 | |
| SCHEMBL9944079 | 0.80 | KMT2A (0.54) | NPC1MEN1KMT2ATAS1R3TAS1R1 | |
| SCHEMBL22871349 | 0.77 | NPC1 (0.50) | PTGFRNPC1MEN1KMT2ACYP3A4 | |
| SCHEMBL9944095 | 0.76 | RARA (0.52) | PTGFRNPC1MEN1KMT2A | |
| SCHEMBL22871249 | 0.76 | PYGL (0.55) | PTGFRNPC1MEN1KMT2ATAS1R3 | |
| SCHEMBL1457789 | 0.76 | LMNA (0.51) | PTGFRNPC1MEN1KMT2ATAS1R3 | |
| SCHEMBL22871382 | 0.75 | PYGL (0.49) | PTGFRNPC1MEN1KMT2ATAS1R3 | |
| SCHEMBL9944094 | 0.74 | HCAR3 (0.58) | NPC1MEN1KMT2ACYP3A4 | |
| SCHEMBL20601603 | 0.74 | PYGL (0.54) | PTGFRNPC1MEN1KMT2ATAS1R3 | |
| SCHEMBL20601795 | 0.74 | TAS1R3 (0.56) | PTGFRNPC1MEN1KMT2ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | PTGFR 1820/4885NPC1 277/4885MEN1 4809/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | PTGFR 1820/4885NPC1 277/4885MEN1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.